TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of human recombinant His-tagged cIAP1 protein BIR3 domain (250 to 350 amino acid residues) using biotinylated-Smac as substrate after over...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of human recombinant His-tagged cIAP1 protein BIR3 domain (250 to 350 amino acid residues) using biotinylated-Smac as substrate after over...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 2.10nMAssay Description:Inhibition of human recombinant His-tagged cIAP1 protein BIR3 domain (250 to 350 amino acid residues) using biotinylated-Smac as substrate after over...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 2.5nMAssay Description:Inhibition of human recombinant His-tagged cIAP1 protein BIR3 domain (250 to 350 amino acid residues) using biotinylated-Smac as substrate after over...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 2.60nMAssay Description:Inhibition of human recombinant His-tagged cIAP1 protein BIR3 domain (250 to 350 amino acid residues) using biotinylated-Smac as substrate after over...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 2.70nMAssay Description:Inhibition of human recombinant His-tagged cIAP1 protein BIR3 domain (250 to 350 amino acid residues) using biotinylated-Smac as substrate after over...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of cIAP BIR2-3 domain (unknown origin)More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Inhibition of human recombinant His-tagged cIAP1 protein BIR3 domain (250 to 350 amino acid residues) using biotinylated-Smac as substrate after over...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 3.40nMAssay Description:Inhibition of human recombinant His-tagged cIAP1 protein BIR3 domain (250 to 350 amino acid residues) using biotinylated-Smac as substrate after over...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of human recombinant His-tagged cIAP1 protein BIR3 domain (250 to 350 amino acid residues) using biotinylated-Smac as substrate after over...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 4.90nMAssay Description:Inhibition of human recombinant His-tagged cIAP1 protein BIR3 domain (250 to 350 amino acid residues) using biotinylated-Smac as substrate after over...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Binding affinity to human 6His-thr cIAP1 BIR3 (253 to 363) domain expressed in Escherichia coli measured after 105 mins in dark by time-resolved fluo...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Competitive inhibition of human cIAP2 BIR3 domain after 2 to 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 5.30nMAssay Description:Displacement of fluorescent SM5F peptide from His-tagged human cIAP2 BIR3 domain expressed in Escherichia coli BL21(DE3) cells by fluorescence polari...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 5.70nMAssay Description:Inhibitory concentration against SO561945 (HIV 1 mutant RT) viral viral infection of MT-4 cellsMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 7.60nMAssay Description:Inhibition of human recombinant His-tagged cIAP1 protein BIR3 domain (250 to 350 amino acid residues) using biotinylated-Smac as substrate after over...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 7.90nMAssay Description:Binding affinity to human 6His-thr cIAP1 BIR3 (253 to 363) domain expressed in Escherichia coli measured after 105 mins in dark by time-resolved fluo...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of cIAP1 BIR3 (154 to 352 residues) (unknown origin) by fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 8.20nMAssay Description:Binding affinity to BIR3 domain of cIAP2 by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 8.20nMAssay Description:Binding affinity to BIR3 domain of cIAP2 by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 8.20nMAssay Description:Competitive inhibition of human cIAP2 BIR3 domain after 2 to 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 8.5nMAssay Description:Competitive inhibition of human cIAP2 BIR3 domain after 2 to 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 8.5nMAssay Description:Binding affinity to BIR3 domain of cIAP2 by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 8.60nMAssay Description:Competitive inhibition of human cIAP2 BIR3 domain after 2 to 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 8.60nMAssay Description:Competitive inhibition of human cIAP2 BIR3 domain after 2 to 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 8.70nMAssay Description:Competitive inhibition of human cIAP2 BIR3 domain after 2 to 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of N-terminal 6x-His-tagged recombinant human cIAP2-BIR3 (244 to 349 residues) expressed in Escherichia coli incubated for 2 hrs after 6 h...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of N-terminal 6x-His-tagged recombinant human cIAP2-BIR3 (244 to 349 residues) expressed in Escherichia coli incubated for 2 hrs after 6 h...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 9.90nMAssay Description:Binding affinity to BIR3 domain of cIAP2 by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: <10nMAssay Description:An in vitro fluorescence polarization (FP) based binding assay was used to test the binding ability of the compounds of the present invention to cert...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: <10nMAssay Description:An in vitro fluorescence polarization (FP) based binding assay was used to test the binding ability of the compounds of the present invention to cert...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of cIAP1 BIR3 (154 to 352 residues) (unknown origin) by fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: <10nMAssay Description:An in vitro fluorescence polarization (FP) based binding assay was used to test the binding ability of the compounds of the present invention to cert...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: <10nMAssay Description:An in vitro fluorescence polarization (FP) based binding assay was used to test the binding ability of the compounds of the present invention to cert...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Binding affinity to cIAP2 BIR3 domain (unknown origin) after 3 hrs by competitive fluorescence polarization assay in presence of Smac-2FMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of N-terminal 6x-His-tagged recombinant human cIAP2-BIR3 (244 to 349 residues) expressed in Escherichia coli incubated for 2 hrs without 6...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Competitive inhibition of human cIAP2 BIR3 domain after 2 to 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of cIAP1 BIR3 (154 to 352 residues) (unknown origin) by fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Competitive inhibition of human cIAP2 BIR3 domain after 2 to 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of N-terminal 6x-His-tagged recombinant human cIAP2-BIR3 (244 to 349 residues) expressed in Escherichia coli incubated for 2 hrs without 6...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Displacement of AVPIAQKSEK-biotin from cIAP2 BIR3 (unknown origin) after 1 hr by DELFIAMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Competitive inhibition of human cIAP2 BIR3 domain after 2 to 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of N-terminal 6x-His-tagged recombinant human cIAP2-BIR3 (244 to 349 residues) expressed in Escherichia coli incubated for 2 hrs after 6 h...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of N-terminal 6x-His-tagged recombinant human cIAP2-BIR3 (244 to 349 residues) expressed in Escherichia coli incubated for 2 hrs after 6 h...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 14nMAssay Description:Inhibition of human recombinant His-tagged cIAP1 protein BIR3 domain (250 to 350 amino acid residues) using biotinylated-Smac as substrate after over...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 14nMAssay Description:Competitive inhibition of human cIAP2 BIR3 domain after 2 to 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 14.5nMAssay Description:Binding affinity to BIR3 domain of cIAP2 by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Binding affinity to BIR3 domain of cIAP2 by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Displacement of AVPIAQKSEK-biotin from cIAP2 BIR3 (unknown origin) after 1 hr by DELFIAMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Takeda Pharmaceutical
Curated by ChEMBL
Takeda Pharmaceutical
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of cIAP1 BIR3 (154 to 352 residues) (unknown origin) by fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair